Scientists engineer decoy protein that neutralises coronavirus: Study

Scientists have engineered a decoy protein which binds to the novel coronavirus and blocks infection in cultured cells, an advance that may lead to a therapeutic or preventive agent against COVID-19.

According to the researchers, including Erik Procko from the University of Illinois, Urbana-Champaign in the US, in order to infect a human cell, a virus must first bind to a receptor protein on the surface of the cell.

For the novel coronavirus SARS-CoV-2, they said this happens via a receptor protein called ACE2, which is found particularly in tissues in the lungs, heart, arteries, kidneys and intestines, playing a number of roles, including the regulation of blood pressure and inflammation.

In the study, published in the journal Science, the researchers produced more than 2,000 mutant versions of ACE2 and analysed how these interacted with the coronavirus.

They found that a combination of three mutations produced a receptor that bound to the virus 50 times more strongly, making it a much more attractive target for the virus than the human body's own version of ACE2.

When the scientists tested a soluble version of the newly engineered receptor, they found that when it is detached from cells, it is free to interact with the virus as a decoy receptor.

"Administering a decoy based on ACE2 might not only neutralise infection, but may have the additional benefit of rescuing lost ACE2 activity and directly treating aspects of COVID-19," Procko said.

According to the scientists, the strong affinity between the virus and the decoy receptor, rivals that of the best antibodies identified to date.

The scientists found that the decoy receptor not only binds to the virus in live tissue cultures, but it also effectively neutralises it, preventing cells from becoming infected.

However, they noted that further research is required to determine whether the decoy receptors could be an effective treatment agent against COVID-19.

Commenting on the findings, Umamaheswari K -- Professor, Centre for Nanotechnology and Advanced Biomaterials at SASTRA University in Tamil Nadu -- who is unrelated to the study, said the research is promising, but added that it is unclear if the decoy protein may protect cells that are already infected.

"I feel it is early to say if this can be translated into a clinical therapeutic. Because the viruses in circulation can probably bind to the decoy, preventing further infection, but there can also be viruses which get into cells," Umamaheswari said.

"The decoy protein may not neutralise these. That is one thing I feel the paper needed to explain further," she added.

Since the decoy protein closely resembles the ACE2 receptor, Umamaheswari said future studies assessing if it interferes with the body's blood pressure regulation process are needed to evaluate its safety in humans.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel